Treating Alcohol Use In Older Adults With Depression

This study has been completed.
Information provided by:
VA Office of Research and Development Identifier:
First received: July 3, 2001
Last updated: September 21, 2009
Last verified: September 2009
The purpose of this study is to test the efficacy combining a treatment for depression with a treatment for alcohol dependence.

Condition Intervention Phase
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Treatment of Late Life Major Depression Complication by Alcohol

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Primary Outcome Measures:
  • Alcohol use` [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 74
Study Start Date: October 1999
Study Completion Date: January 2005
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Placebo Comparator: 2
Drug: Placebo

Detailed Description:
This study aims to study 80 patients with comorbid alcohol dependence and a depressive syndrome. After appropriate detoxification, patients are started on either naltrexone 50 mg or placebo. After one week, sertraline is added in an open label fashion. It is hypothesized that those patients receiving combination therapy will last 3 months with follow-up tracking lasting 1 year.

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 55
  • Current depressive syndrome
  • Current alcohol dependence
  • No psychosis
  • No opioid or cocaine abuse or dependence

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00018824

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
VA Office of Research and Development
Principal Investigator: David W. Oslin, MD University of Pennsylvania
  More Information

Responsible Party: Oslin, David - Principal Investigator, Department of Veterans Affairs Identifier: NCT00018824     History of Changes
Other Study ID Numbers: MHBS-009-98S
Study First Received: July 3, 2001
Last Updated: September 21, 2009
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Depressive Disorder
Behavioral Symptoms
Mental Disorders
Mood Disorders
Central Nervous System Agents
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 27, 2015